Repeat intravenous r-tPA administration four days after initial thrombolytic therapy for recurrent ischemic stroke: A case report and review of literature
Stroke is a significant source of morbidity and mortality within the United States. The current standard of care for treatment of acute ischemic stroke is intravenous recombinant tissue-type plasminogen activator (IV r-tPA). However, IV r-tPA is contraindicated within 3 months of a previous stroke d...
| Auteurs principaux: | , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
Elsevier
2021-03-01
|
| Collection: | Interdisciplinary Neurosurgery |
| Sujets: | |
| Accès en ligne: | http://www.sciencedirect.com/science/article/pii/S2214751920304989 |